Sanofi U S appeals court upholds ruling in Lovenox patent dispute: related news

U.S. Patent Office allows another significant VNUS patent

Add our medical news to digg - U.S. Patent Office allows another significant VNUS patent Add our medical news to NewsVine - U.S. Patent Office allows another significant VNUS patent Add our medical news to Fark - U.S. Patent Office allows another significant VNUS patent Add our medical news to Furl - U.S. Patent Office allows another significant VNUS patent Add our medical news to Shadows - U.S. Patent Office allows another significant VNUS patent Add our medical news to YahooMyWeb - U.S. Patent Office allows another significant VNUS patent Add our medical news to Reddit -U.S. Patent Office allows another significant VNUS patent Add our medical news to StumbleUpon - U.S. Patent Office allows another significant VNUS patent Add our medical news to Facebook - U.

Sanofi: U.S. appeals court upholds ruling in Lovenox patent dispute

Sanofi-Aventis said Thursday a federal appeals court has upheld the lower court's ruling against the company in its patent dispute against Amphastar Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.

febit receives U.S. patent for microfluidic extraction method

Add our medical news to digg - febit receives U.S. patent for microfluidic extraction method Add our medical news to NewsVine - febit receives U.S. patent for microfluidic extraction method Add our medical news to Fark - febit receives U.S. patent for microfluidic extraction method Add our medical news to Furl - febit receives U.S. patent for microfluidic extraction method Add our medical news to Shadows - febit receives U.S. patent for microfluidic extraction method Add our medical news to YahooMyWeb - febit receives U.S. patent for microfluidic extraction method Add our medical news to Reddit -febit receives U.S. patent for microfluidic extraction method Add our medical news to StumbleUpon - febit receives U.S. patent for microfluidic extraction method Add our medical news to Facebook - febit receives U.

Patent Appeals System Under Constitutional Attack

Goobermunch sends in a law.com article going into questions about the validity of recent patent rulings (within the past eight years) by the Board of Patent Appeals and Interferences, due to the unconstitutionality of the method for appointing patent and trademark appeals judges. The problem arises because the patent appeals judges were appointed by the Director of the Patent and Trademark Office, rather than the Secretary of Commerce. Under Article 2, Section 2 of the U.S. Constitution, the power to appoint "inferior officers" of the government may be vested in "in the President alone, in the courts of law, or in the heads of departments." The patent appeals judges are likely inferior officers, and therefore must be appointed by the President, the courts, or a department head.

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms...

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms Validity of NICE's Patent RA'ANANA, Israel, May 26 /PRNewswire-FirstCall/ -- NICE Systems (NASDAQ: NICE) announced today that in a patent infringement case brought against Verint Americas, Inc. (formerly Witness Systems, Inc.) in the Federal District Court for Northern Georgia in Atlanta, the court found that certain Witness products, which were named in this case, do not infringe NICE's VoIP patent 6871229. NICE intends to appeal this decision. The court rejected Verint's claims challenging the validity of NICE's patent and reaffirmed its validity. The US Patent Office has also, prior to the trial, denied Verint's request for re-examination of the same patent.

Sanofi: U.S. appeals court upholds ruling in Lovenox patent dispute? ? 55 mins ago

Warren Buffett's Berkshire Hathaway Eliminates Ameriprise Stake, Adds to Ingersoll & Kraft HoldingsÂ

Sanofi-Aventis 'considering legal options'; U.S. Lovenox patent 'unenforceable'

PARIS (Thomson Financial) - Sanofi-Aventis said it is "considering all its legal options" after the U.S. Court of Appeals upheld an earlier ruling in the Lovenox anti-coagulant patent infringement suit against Amphastar and Teva Pharmaceutical Industries.

Oracle win on Mangosoft patent claim upheld by court

Oracle's database software doesn't infringe a patent by smaller rival Mangosoft, a U.S. appeals court ruled, upholding a lower-court finding. A three-judge panel of the U.S. Court of Appeals for the Federal Circuit on Wednesday upheld a March 2006 ruling in favor of Oracle, the world's third-biggest software maker. Mangosoft sued in 2002, claiming that Oracle's 9i and 10g database software infringed its patent for technology that lets a network of computers share memory to better structure data storage systems. The company had originally sought $500 million from Oracle. Redwood City-based Oracle saw its stock rise 11 cents to $21.78 in Nasdaq trading. Representatives from Nashua, N.H.-based Mangosoft didn't return a call seeking comment.

Quanta Computer v. LG Electronics: Supreme Court Broadens Application of Patent Exhaustion Doctrine

On June 9, 2008, in a 9-0 unanimous opinion in Quanta Computer v. LG Electronics, the Supreme Court once again overturned the Court of Appeals for the Federal Circuit and issued an opinion that limits the rights of patent owners, this time under the patent exhaustion doctrine. Under this longstanding doctrine, the first authorized sale of a patented item terminates the patent owner’s patent rights in that item. In Quanta Computer, the Supreme Court extended the patent exhaustion doctrine to method patents and held that the authorized, unrestricted sale by a licensee of components embodying the essential features of a patented apparatus and patented method and having no reasonable use other than to practice the patented inventions exhausts the patent owner’s right in the patents.

Appeals Court Reinstates One of Two Alcatel Patent Cases

A federal appeals court reinstated one of two patent cases tossed out last year in the ongoing user-interface technology dispute pitting Alcatel-Lucent against Microsoft and Dell. The appeals court said the San Diego district court erred in its determination of a "terminal device" and remanded the case, which was dismissed, back to the court for further proceedings.

Quanta Decision Illustrates Case Against Specialized Patent Court

I agree with Mike that the Quanta v. LG decision was a big victory for common sense in patent law. I think it's worth taking a step back to note that this is a continuation of the trend that Mike identified last year. This is at least the fourth time in as many years that the Supreme Court has taken a patent law case, and in every case they've overruled a bad decision by the US Court of Appeals for the Federal Circuit, which has jurisdiction over patent appeals. The Federal Circuit has spent the last 15 years making a mess of patent law, and the Supreme Court has finally started to notice and is working to clean up the Federal Circuit's messes. But it's hard because patents are one of a handful of major issues on its docket, whereas the Supreme Court has lots of other subjects it needs to deal with.

Affinity Technology Group, Inc.: Court of Appeals Publishes Opinion in Patent Cases

COLUMBIA, S.C. (Business Wire) -- Affinity Technology Group, Inc. (OTCBB: AFFI) today announced that the United States Court of Appeals for the Federal Circuit (the "Appeals Court") has published its opinion in the cases of its subsidiary, decisioning.com versus Federated Department Stores, TD Ameritrade and HSBC Finance Corporation. The principal issues decided by the Appeals Court involved the definition of certain terms which were the basis for the summary judgment order issued by the United States District Court for the District of South Carolina in which the cases against Federated, TD Ameritrade and HSBC were dismissed in 2007. The terms in dispute were the result of a Markman hearing held in December 2006 and included the terms "remote interface," "verify the applicant's identity" and "compare.

Environmental Control Corporation Acquires Second Canadian Patent

VANCOUVER, BC -- 05/20/08 -- Environmental Control Corporation ("EVCC") (OTCBB: EVCC) -- It is with great pleasure that Environmental Control Corporation ("EVCC") (OTCBB: EVCC) announces the approval of its second Canadian Patent. The Reverse Flow Catalytic Muffler, Canadian Patent # 2,448,648, now accompanies Canadian Patent # 2,448,742 -- The Combined Catalytic Muffler. Other intellectual property currently held by EVCC includes two U.S. Patents: The Reverse Flow Catalytic Muffler (U.S. Patent # 7,018,590) and The Combined Catalytic Muffler (U.S. Patent # 6,622,482); and one pending patent in Europe: the Reverse Flow Catalytic Muffler (Patent Application # 02742591.7). It is anticipated that the European patent application will be approved and registered in the near future.

U.S. Patent on Cytori's Celution System Technology Issued; Celution System Commercialization not Impacted by Recent 6,777,231 Patent Inventorship Decision

SAN DIEGO--(BUSINESS WIRE)--Jun 24, 2008 - U.S. Patent No. 7,390,484 ("the '484 patent") covering Cytori's (NASDAQ:CYTX) Celution(R) System technology was issued today by the United States Patent and Trademark Office. The '484 patent provides Cytori critical market protection for its commercialization of the Celution System in the United States, where the Company is seeking regulatory approval. The '484 patent also protects Cytori's rights to manufacture the Celution Systems in the United States for commercialization into all markets, including Europe and Asia-Pacific, where the device is currently being sold. Other related patent filings are in progress around the globe.

U.S. court overturns patent ruling for LG vs Quanta

WASHINGTON (Reuters) - The U.S. Supreme Court overturned on Monday a ruling in favor of South Korea's LG Electronics Inc <066570.KS> in a dispute with Quanta Computer Inc <2382.TW> of Taiwan over whether the license to a patent automatically passes to whoever purchases the goods.

Microsoft Patent Challenge Update: Majority of Microsoft Re-Examination Challenges of Avistar's U.S. Patents Rejected by U.S. Patent Office

SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ -- Avistar Communications Corporation AVSR announced today that the U.S. Patent Office has now completed its review of Microsoft's requests for patent re-examination of the complete Avistar U.S. patent portfolio. The USPTO has now rejected 19 re-exam applications and has agreed to re-examine, either in part or fully, 10 existing patents.

Microsoft Patent Challenge Update: Majority of Microsoft Re-Examination Challenges of Avistar's U.S. Patents Rejected by U.S. Patent Office

SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ -- Avistar Communications Corporation (Nasdaq: AVSR) announced today that the U.S. Patent Office has now completed its review of Microsoft's requests for patent re-examination of the complete Avistar U.S. patent portfolio. The USPTO has now rejected 19 re-exam applications and has agreed to re-examine, either in part or fully, 10 existing patents.

Rambus Reports Favorable Ruling By Appeals Court In Patent Case With Samsung [RMBS]

4/29/2008 2:54:53 PM Rambus Inc. (RMBS), a California based developer of chip interface technologies, Tuesday reported that the Court of Appeals for the Federal Circuit has issued a favorable decision in the pending patent infringement case with Samsung. The ruling cancels an earlier order by the Federal District Court for the Eastern District of Virginia and dismisses the claims put forth by Samsung.

U.S. Patent and Trademark Office Grants Re-Examination of Patent 6,881,571 on Behalf of Jivan

Jivan Biologics, Inc. announced today that the United States Patent and Trademark Office has ordered the re-examination of U.S. Patent No. 6,881,571. The serial number for the reexamination is 90/009,017. This patent is the sole subject of the suit ExonHit Therapeutics SA and ExonHit Therapeutics, Inc. filed against Jivan Biologics Inc. on March 12, 2007 in the U.S. District Court, Northern District of California.

U.S. Patent Office Allows Another Significant VNUS Patent

SAN JOSE, Calif., May 9 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. today announced that the U.S. Patent & Trademark Office has decided to allow a second continuation patent application related to the patents in the VNUS patent infringement lawsuit against suppliers of endovenous laser products. This comes on the heels of the Patent Office's decision last month to allow VNUS a separate patent application, also filed as a continuation of one of the patents in the lawsuit.

U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent

NEW YORK--(BUSINESS WIRE)--April 30, 2008 - Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of the claims of Pfizer's '893 basic patent for Lipitor. The Patent Office had conducted a re-examination of the '893 patent in response to a request by a law firm that represented the generic company Ranbaxy Laboratories Limited. The patent, which expires in March 2010 (including pediatric exclusivity), was previously the subject of litigation against Ranbaxy, in which Pfizer prevailed in both the trial and appeal courts.

U.S. Patent and Trademark Office Grants Re-Examination of Patent 6,881,571 on Behalf of Jivan

LARKSPUR, Calif.--(BUSINESS WIRE)--May 19, 2008--Jivan Biologics, Inc. announced today that the United States Patent and Trademark Office has ordered the re-examination of U.S. Patent No. 6,881,571. The serial number for the reexamination is 90/009,017. This patent is the sole subject of the suit ExonHit Therapeutics SA and ExonHit Therapeutics, Inc. filed against Jivan Biologics Inc. on March 12, 2007 in the U.S. District Court, Northern District of California.

Analysis: appeals court unlikely to fix software patent mess

Last Thursday the United States Court of Appeals for the Federal Circuit heard oral arguments in In Re Bilski, one of the most closely-watched patent cases in years. The case concerns a patent application of one Bernie Bilski for "a method for managing the consumption risk costs of a commodity sold by a commodity provider" by engaging in a series of financial transactions. The patent was rejected by the patent office as too abstract, and Mr. Bilski appealed the decision to the courts. The Federal Circuit, which has been under fire for its liberal rules for patenting abstract concepts, decided to use the case as an opportunity to revisit the issue. In its call for amicus briefs, the Federal Circuit explicitly asked for opinions on whether it should reconsider its State Street decision and tighten limits on abstract ideas.

Appeals court issues split ruling in Alcatel-Lucent patent case

A federal appeals court issued a split ruling on Alcatel-Lucent's patent infringement lawsuit against Microsoft and Dell.

Barr confirms patent challenge of Prevacid SoluTab tablets

Add our medical news to digg - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to NewsVine - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Fark - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Furl - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Shadows - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to YahooMyWeb - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Reddit -Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to StumbleUpon - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Facebook - Barr confirms patent challenge of Prevacid SoluTab tablets

Search took 0.59 seconds.